Moderna, Inc. Common Stock (MRNA) Stock Price
MRNAStock
$137.99+463.92%52W
Market Cap$55.09B
P/E—
PEG Ratio—
Div yield—
Beta1.17
MRNA Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)161.21%
Price vs S&P 500 (4W)148.71%
VGM Score57.96
MRNA Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$2.06 | -$1.97 | +4.33%(+$0.09) | |
| Q1 2026 | -$3.88 | -$3.40 | +12.37%(+$0.48) | |
| Q4 2025 | -$2.60 | -$2.11 | +18.88%(+$0.49) | |
| Q3 2025 | -$2.18 | -$0.51 | +76.60%(+$1.67) | |
| Q2 2025 | -$2.97 | -$2.13 | +28.28%(+$0.84) |
MRNA Analyst Recommendations
May 2026
Jun 2026
Jul 2026
Aug 2026
3.23
2.80
2.80
3.23
Industry Peers — Biological Products(183)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
MRNAModerna, Inc. Common Stock | D | C | A | $137.99 |
| AMGNAmgen Inc | C | C | B | $432.42 |
| GILDGilead Sciences Inc | C | B | B | $145.68 |
| ARGXargenx SE American Depositary Shares | D | A | B | $1023.21 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $207.88 |
| BIIBBiogen Inc. Common Stock | C | D | B | $218.50 |
| BNTXBioNTech SE American Depositary Share | C | C | C | $102.08 |
| NBIXNeurocrine Biosciences Inc | C | B | C | $154.06 |
| EXELExelixis Inc | C | B | B | $54.45 |
| HALOHalozyme Therapeutics, Inc. | C | B | B | $105.35 |
| TECHBio-Techne Corp. | D | C | B | $72.35 |
About Moderna, Inc. Common Stock
Moderna is a biotechnology company leveraging its validated mRNA platform to develop therapeutics across infectious disease, oncology, cardiovascular disease, and rare genetic diseases. The company commercially validated its technology with its FDA-authorized COVID-19 vaccine in 2020. As of August 2025, Moderna maintains a pipeline of 35 mRNA candidates in clinical development.